Neurocrine Biosciences Inc NBIX
Neurocrine Biosciences Inc (Nasdaq: NBIX) is a CNS/neurology/psychiatry drug developer. Its lead program, INGREZZA (valbenazine), is in Phase 3 for tardive dyskinesia; chorea associated with Huntington's disease.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| INGREZZA (valbenazine) | tardive dyskinesia; Huntington's chorea | small molecule | Approved |
| CRENESSITY (crinecerfont) | classic congenital adrenal hyperplasia | small molecule | Approved |
| VYKAT XR (diazoxide choline) | hyperphagia in Prader-Willi syndrome | small molecule | Approved |
| osavampator | major depressive disorder | small molecule | Phase 3 |
| direclidine | schizophrenia | small molecule | Phase 3 |
| NBI-1117570 | schizophrenia (dual M1/M4 agonist) | small molecule | Phase 2 |
| crinecerfont (pediatric <4 yrs) | CAH in children 3 months to under 4 years | small molecule | Phase 2 |
| NBI-1065890 | tardive dyskinesia | small molecule | Phase 2 |
| NBIP-01435 | CAH | unclear | Phase 1 |
| NBIP-2118 | obesity (CRF2 peptide agonist) | protein/peptide | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.